Related Experiment Videos
[Radioactive iodine therapy in Graves' hyperthyroidism].
Vânia A Andrade1, Jorge Luiz Gross, Ana Luiza Maia
1Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS.
Arquivos Brasileiros De Endocrinologia E Metabologia
|December 22, 2004
Summary
Graves' disease, a common cause of hyperthyroidism, is triggered by TSH receptor-activating autoantibodies. This review examines treatment options like antithyroid drugs (ATD) and radioactive iodine (131I), including predictors of treatment success.
Area of Science:
- Endocrinology
- Immunology
Context:
- Graves' disease is the leading cause of hyperthyroidism.
- Thyrotoxicosis results from autoantibodies stimulating the TSH receptor.
- The disease has complex multifactorial etiology involving genetic and environmental factors.
Purpose:
- To review current treatment strategies for Graves' disease.
- To discuss the efficacy and safety of antithyroid drugs (ATD) and radioactive iodine (131I).
- To explore predictors of treatment failure and emerging therapeutic approaches.
Summary:
- Antithyroid drugs (ATD) remain the primary treatment for mild cases, children, adolescents, and pregnant individuals.
- Radioactive iodine (131I) is a safe, cost-effective, and definitive therapy, increasingly favored for long-term management.
- Surgery is reserved for specific cases where ATD fail and 131I is unsuitable.
Impact:
- Provides an updated overview of Graves' disease management.
- Highlights the role of 131I as a definitive treatment.
- Informs clinical decisions regarding the selection of appropriate therapies based on patient-specific factors.